Strategic Investment Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Strategic Investment Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,044	Closed	-$801K	–	220
2022 Q2	$801K	Sell	10,044 -211	-2%	-$20K	0.16%	98
2022 Q1	$1.08M	Buy	10,255 +24	+0.2%	+$2.34K	0.2%	84
2021 Q4	$1.1M	Buy	10,231 +198	+2%	+$21.6K	0.21%	94
2021 Q3	$1.1M	Buy	10,033 +654	+7%	+$67.9K	0.24%	82
2021 Q2	$878K	Buy	9,379 +3,710	+65%	+$341K	0.2%	106
2021 Q1	$522K	Buy	+5,669	New	+$478K	0.14%	125

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Strategic Investment Advisors's HZNP Position: Q3 2022 in Review

Strategic Investment Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 10,044 shares — an estimated $801K sold.

Strategic Investment Advisors first reported a position in HZNP in Q1 2021 and held it in 6 quarters. The position peaked at $1.1M in Q4 2021. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Strategic Investment Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Strategic Investment Advisors sold 10,044 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $801K.
Strategic Investment Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and held it in 6 quarters.
Strategic Investment Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.1M in Q4 2021.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Strategic Investment Advisors's 13F filing for Q3 2022, filed 27 Oct 2022.